Published in J Antimicrob Chemother on August 18, 2009
Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat Rev Microbiol (2011) 2.68
Nonthermal dielectric-barrier discharge plasma-induced inactivation involves oxidative DNA damage and membrane lipid peroxidation in Escherichia coli. Antimicrob Agents Chemother (2011) 1.58
Antibiotics in the clinical pipeline at the end of 2015. J Antibiot (Tokyo) (2016) 1.04
Neutral metallated and meso-substituted porphyrins as antimicrobial agents against gram-positive pathogens. Eur J Clin Microbiol Infect Dis (2011) 0.99
Investigation of the potential for mutational resistance to XF-73, retapamulin, mupirocin, fusidic acid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus isolates during a 55-passage study. Antimicrob Agents Chemother (2010) 0.96
Drug discovery of antimicrobial photosensitizers using animal models. Curr Pharm Des (2011) 0.92
Advances in MRSA drug discovery: where are we and where do we need to be? Expert Opin Drug Discov (2013) 0.82
Further characterization of Bacillus subtilis antibiotic biosensors and their use for antibacterial mode-of-action studies. Antimicrob Agents Chemother (2011) 0.80
Elucidation of the Mode of Action of a New Antibacterial Compound Active against Staphylococcus aureus and Pseudomonas aeruginosa. PLoS One (2016) 0.79
Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review. Curr Top Med Chem (2014) 0.79
Repurposing Toremifene for Treatment of Oral Bacterial Infections. Antimicrob Agents Chemother (2017) 0.76
Nordihydroguaiaretic acid enhances the activities of aminoglycosides against methicillin- sensitive and resistant Staphylococcus aureus in vitro and in vivo. Front Microbiol (2015) 0.75
Photoinactivation of Staphylococcus aureus using protoporphyrin IX: the role of haem-regulated transporter HrtA. Appl Microbiol Biotechnol (2015) 0.75
Membrane Active Antimicrobial Peptides: Translating Mechanistic Insights to Design. Front Neurosci (2017) 0.75
Comparing the action of HT61 and chlorhexidine on natural and model Staphylococcus aureus membranes. J Antibiot (Tokyo) (2017) 0.75
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 14.41
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med (2010) 4.38
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer (2008) 2.86
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med (2010) 2.72
Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat Rev Microbiol (2011) 2.68
The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resist Updat (2003) 2.07
Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement. Lancet Infect Dis (2008) 1.96
The use of immunoglobulin g4 immunostaining in diagnosing pancreatic and extrapancreatic involvement in autoimmune pancreatitis. Clin Gastroenterol Hepatol (2007) 1.83
The isoleucyl-tRNA synthetase mutation V588F conferring mupirocin resistance in glycopeptide-intermediate Staphylococcus aureus is not associated with a significant fitness burden. J Antimicrob Chemother (2003) 1.72
Prospects for aminoacyl-tRNA synthetase inhibitors as new antimicrobial agents. Antimicrob Agents Chemother (2005) 1.71
Response of Escherichia coli hypermutators to selection pressure with antimicrobial agents from different classes. J Antimicrob Chemother (2002) 1.57
External quality assurance of HER2 FISH and ISH testing: three years of the UK national external quality assurance scheme. Am J Clin Pathol (2009) 1.57
A fusidic acid-resistant epidemic strain of Staphylococcus aureus carries the fusB determinant, whereas fusA mutations are prevalent in other resistant isolates. Antimicrob Agents Chemother (2004) 1.52
In vivo transfer of high-level mupirocin resistance from Staphylococcus epidermidis to methicillin-resistant Staphylococcus aureus associated with failure of mupirocin prophylaxis. J Antimicrob Chemother (2005) 1.47
Molecular basis of fusB-mediated resistance to fusidic acid in Staphylococcus aureus. Mol Microbiol (2006) 1.44
Analysis of mupirocin resistance and fitness in Staphylococcus aureus by molecular genetic and structural modeling techniques. Antimicrob Agents Chemother (2004) 1.39
Linezolid and tiamulin cross-resistance in Staphylococcus aureus mediated by point mutations in the peptidyl transferase center. Antimicrob Agents Chemother (2008) 1.35
Analysis of mutational resistance to trimethoprim in Staphylococcus aureus by genetic and structural modelling techniques. J Antimicrob Chemother (2009) 1.35
Preclinical evaluation of novel antibacterial agents by microbiological and molecular techniques. Expert Opin Investig Drugs (2004) 1.31
Recent advances in operant conditioning technology: a versatile and affordable computerized touchscreen system. Behav Res Methods Instrum Comput (2004) 1.30
Digital slides: present status of a tool for consultation, teaching, and quality control in pathology. Pathol Res Pract (2009) 1.29
Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus. J Antimicrob Chemother (2008) 1.25
Dissecting structural and functional diversity of the lantibiotic mersacidin. Chem Biol (2009) 1.25
Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. Am J Clin Pathol (2009) 1.23
Comparison of assays for detection of agents causing membrane damage in Staphylococcus aureus. J Antimicrob Chemother (2004) 1.22
Insertional inactivation of mutS in Staphylococcus aureus reveals potential for elevated mutation frequencies, although the prevalence of mutators in clinical isolates is low. J Antimicrob Chemother (2002) 1.20
Anti-staphylococcal activity and mode of action of clofazimine. J Antimicrob Chemother (2004) 1.17
Anti-staphylococcal activity of indolmycin, a potential topical agent for control of staphylococcal infections. J Antimicrob Chemother (2004) 1.08
Cyclin D1 overexpression permits the reproducible detection of senescent human vascular smooth muscle cells. Ann N Y Acad Sci (2007) 1.07
The target of daptomycin is absent from Escherichia coli and other gram-negative pathogens. Antimicrob Agents Chemother (2012) 1.06
XF-70 and XF-73, novel antibacterial agents active against slow-growing and non-dividing cultures of Staphylococcus aureus including biofilms. J Antimicrob Chemother (2010) 1.04
Structure-based discovery of antibacterial drugs. Nat Rev Microbiol (2010) 1.04
Increased mutability of Staphylococci in biofilms as a consequence of oxidative stress. PLoS One (2012) 1.03
Microarray analysis of senescent vascular smooth muscle cells: A link to atherosclerosis and vascular calcification. Exp Gerontol (2009) 1.03
The nature of Staphylococcus aureus MurA and MurZ and approaches for detection of peptidoglycan biosynthesis inhibitors. Mol Microbiol (2009) 1.01
Mechanisms of the post-antibiotic effects induced by rifampicin and gentamicin in Escherichia coli. J Antimicrob Chemother (2006) 0.99
Functional and biochemical analysis of the Chlamydia trachomatis ligase MurE. J Bacteriol (2009) 0.98
Biological properties of novel antistaphylococcal quinoline-indole agents. Antimicrob Agents Chemother (2003) 0.97
Functional and biochemical analysis of Chlamydia trachomatis MurC, an enzyme displaying UDP-N-acetylmuramate:amino acid ligase activity. J Bacteriol (2003) 0.97
Characterization of global patterns and the genetics of fusidic acid resistance. Clin Infect Dis (2011) 0.97
Standardization of positive controls in diagnostic immunohistochemistry: recommendations from the International Ad Hoc Expert Committee. Appl Immunohistochem Mol Morphol (2015) 0.97
Biochemical characterisation of the chlamydial MurF ligase, and possible sequence of the chlamydial peptidoglycan pentapeptide stem. Arch Microbiol (2012) 0.96
Investigation of the potential for mutational resistance to XF-73, retapamulin, mupirocin, fusidic acid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus isolates during a 55-passage study. Antimicrob Agents Chemother (2010) 0.96
Ectopic prostatic tissue in the uterine cervix and vagina: report of a series with a detailed immunohistochemical analysis. Am J Surg Pathol (2006) 0.95
The silver cation (Ag+): antistaphylococcal activity, mode of action and resistance studies. J Antimicrob Chemother (2012) 0.95
Staphylococcus aureus biofilms promote horizontal transfer of antibiotic resistance. Antimicrob Agents Chemother (2013) 0.93
Delayed development of linezolid resistance in Staphylococcus aureus following exposure to low levels of antimicrobial agents. Antimicrob Agents Chemother (2008) 0.90
Escherichia coli mutators present an enhanced risk for emergence of antibiotic resistance during urinary tract infections. Antimicrob Agents Chemother (2004) 0.89
Spitz nevus with Homer-Wright rosette-like structures. Am J Dermatopathol (2012) 0.88
FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. J Exp Clin Cancer Res (2012) 0.88
Furanyl-rhodanines are unattractive drug candidates for development as inhibitors of bacterial RNA polymerase. Antimicrob Agents Chemother (2010) 0.87
Characterization of cellular senescence mechanisms in human corneal endothelial cells. Aging Cell (2011) 0.86
Diazenedicarboxamides as inhibitors of D-alanine-D-alanine ligase (Ddl). Bioorg Med Chem Lett (2007) 0.86
Assessment of a microplate method for determining the post-antibiotic effect in Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother (2004) 0.86
Intrinsic novobiocin resistance in Staphylococcus saprophyticus. Antimicrob Agents Chemother (2007) 0.85
Deletion of the multiple-drug efflux pump AcrAB in Escherichia coli prolongs the postantibiotic effect. Antimicrob Agents Chemother (2005) 0.85
Discovery of new inhibitors of the bacterial peptidoglycan biosynthesis enzymes MurD and MurF by structure-based virtual screening. Bioorg Med Chem (2009) 0.85
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists. J Med Chem (2009) 0.83
Zeocin resistance suppresses mutation in hypermutable Escherichia coli. Microbiology (2003) 0.83
Calcium-binding phospholipids as a coating material for implant osteointegration. J R Soc Interface (2006) 0.82
A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay. Am J Clin Pathol (2011) 0.82
External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme. J Clin Pathol (2006) 0.82
Activity of and development of resistance to corallopyronin A, an inhibitor of RNA polymerase. Antimicrob Agents Chemother (2011) 0.82
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine. Part 3: Technical Validation of Immunohistochemistry (IHC) Assays in Clinical IHC Laboratories. Appl Immunohistochem Mol Morphol (2017) 0.82
Population diversification in Staphylococcus aureus biofilms may promote dissemination and persistence. PLoS One (2013) 0.81
Antistaphylococcal activity of the novel cephalosporin CB-181963 (CAB-175). J Antimicrob Chemother (2005) 0.81
Reprocessing and sterilization of single-use electrophysiological catheters: removal of organic carbon and protein surface residues. J AOAC Int (2009) 0.81
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma. J Cancer Res Clin Oncol (2013) 0.81
Rapid multiplexed flow cytometric assay for botulinum neurotoxin detection using an automated fluidic microbead-trapping flow cell for enhanced sensitivity. Anal Chem (2009) 0.81
2-Aminotetralones: novel inhibitors of MurA and MurZ. Bioorg Med Chem Lett (2008) 0.80
Lack of evidence for involvement of hypermutability in emergence of vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother (2003) 0.80
Chromogenic in situ hybridization: a multicenter study comparing silver in situ hybridization with FISH. Am J Clin Pathol (2009) 0.80
6-Arylpyrido[2,3-d]pyrimidines as novel ATP-competitive inhibitors of bacterial D-alanine:D-alanine ligase. PLoS One (2012) 0.80
Further characterization of Bacillus subtilis antibiotic biosensors and their use for antibacterial mode-of-action studies. Antimicrob Agents Chemother (2011) 0.80
Variation in rates of oestrogen receptor positivity in breast cancer again. BMJ (2002) 0.79
In vitro activity of XF-73, a novel antibacterial agent, against antibiotic-sensitive and -resistant Gram-positive and Gram-negative bacterial species. Int J Antimicrob Agents (2010) 0.79
A UK NEQAS ICC and ISH multicentre study using the Kreatech Poseidon HER2 FISH probe: intersite variation can be rigorously controlled using FISH. Histopathology (2010) 0.79
Information technology and hospice palliative care: social, cultural, ethical and technical implications in a rural setting. Inform Health Soc Care (2011) 0.78
Suitability of infiltrative lobular breast carcinoma for anti-human epidermal growth factor receptor 2 treatment after the ASCO/CAP and 2009 St Gallen International Expert Consensus meeting. Histopathology (2010) 0.78
8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists. J Med Chem (2009) 0.78
Multi-gigabit/s underwater optical communication link using orbital angular momentum multiplexing. Opt Express (2016) 0.78
Small molecule inhibitors of peptidoglycan synthesis targeting the lipid II precursor. Biochem Pharmacol (2011) 0.78
Discovery of new inhibitors of D-alanine:D-alanine ligase by structure-based virtual screening. J Med Chem (2008) 0.78
A de novo designed inhibitor of D-Ala-D-Ala ligase from E. coli. Angew Chem Int Ed Engl (2005) 0.78
Can the intestinal dysmotility of critical illness be differentiated from postoperative ileus? Curr Gastroenterol Rep (2011) 0.78
Macrocyclic inhibitors of the bacterial cell wall biosynthesis enzyme MurD. Bioorg Med Chem Lett (2003) 0.77
Synthesis and evaluation of imidazo[1,5-a]pyrazines as corticotropin releasing hormone receptor ligands. Bioorg Med Chem Lett (2002) 0.77
Ellipticines and 9-acridinylamines as inhibitors of D-alanine:D-alanine ligase. Bioorg Med Chem (2011) 0.77